全球青光眼市场评估：依疾病类型、药物类别、分布、地区、机会、预测（2017-2031）

全球青光眼市场规模预计将从 2023 年的 85.3 亿美元增至 2031 年的 127.5 亿美元，预计 2024-2031 年的复合年增长率为 5.15%。由于青光眼盛行率的增加以及投资者和市场参与者兴趣的增加，预计在预测期内，青光眼治疗的市场需求将呈指数级增长。

青光眼是一组影响视神经的眼部疾病。视神经将视觉讯息从眼睛传递到大脑，对于良好的视力至关重要。青光眼通常会因眼压升高而导致视神经损伤，但即使眼压正常也可能发生。青光眼可以在任何年龄发生，但年龄越大，发生的可能性就越大。青光眼是 60 岁以上失明的主要原因之一。青光眼的症状因疾病的类型和阶段而异。最常见的青光眼类型是开角型青光眼，而其他类型（例如闭角型青光眼）则较不常见。开角型青光眼的早期阶段没有任何症状，患者只能看到横向视野中的盲点。急性闭角型青光眼的症状包括严重头痛、视力模糊、眼睛充血、严重眼痛、噁心和呕吐。目前，全世界有 8000 万人患有青光眼。超过 300 万美国人患有青光眼，其中 270 万人（40 岁及以上）患有开角型青光眼，这是最常见的类型。根据《青光眼杂誌》2023 年 6 月发表的报告，预计到 2040 年，全球将有 2,200 万视障人士受到青光眼的影响。世界青光眼週是由世界青光眼协会组织的国际倡议。世界青光眼协会邀请患者、眼保健提供者、医疗保健专业人员和当地社区帮助组织全球宣传工作。青光眼是可预防性失明的主要原因，并在世界各地提出了独特的课题。这里的目标是教育每个人定期检查眼睛和视神经，以便儘早发现青光眼并开始治疗以防止视力丧失。

本报告研究和分析了全球青光眼市场，提供市场规模和预测、市场动态以及主要参与者的状况。

目录

第一章专案范围与定义

第二章研究方法

第 3 章执行摘要

第四章全球青光眼市场展望（2017-2031）

• 市场规模分析与预测
  • 金额
• 市占率分析与预测
  • 依疾病类型
  • 依药物类别
  • 依分布
  • 按地区
  • 市占率分析：按公司划分（金额）（前 5 名公司及其他 - 2023 年）
• 市场地图分析（2023 年）
  • 依疾病类型
  • 依药物类别
  • 依分布
  • 按地区

第五章北美青光眼市场展望（2017-2031）

• 市场规模分析与预测
  • 金额
• 市占率分析与预测
  • 依疾病类型
  • 依药物类别
  • 依分布
  • 分享：依国家/地区
• 每个国家市场的评估
  • 美国青光眼市场展望（2017-2031）
  • 加拿大
  • 墨西哥

第六章欧洲青光眼市场展望（2017-2031）

• 德国
• 法国
• 义大利
• 英国
• 俄罗斯
• 荷兰
• 西班牙
• 波兰

第七章亚太地区青光眼市场展望（2017-2031）

• 印度
• 中国
• 日本
• 澳大利亚
• 越南
• 韩国
• 印尼
• 菲律宾

第 8 章南美洲青光眼市场前景（2017-2031）

• 巴西
• 阿根廷

第 9 章中东与非洲青光眼市场前景（2017-2031 年）

• 沙乌地阿拉伯
• 阿拉伯联合大公国
• 南非
• 以色列

第10章供需分析

第十一章进出口分析

第十二章价值链分析

第 13 章波特五力分析

第14章PESTLE分析

第十五章价格分析

第 16 章市场动态

• 市场推动因素
• 市场课题

第十七章市场趋势与发展

第 18 章监理架构与创新

• 临床试验
• 监理机关的核准

第十九章专利状况

第 20 章个案研究

第21章竞争态势

• 前 5 名市场领导者的竞争矩阵
• 前 5 名的公司的 SWOT 分析
• 前10名主要企业状况
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Novartis AG.
  • Teva Pharmaceuticals Industries Ltd.
  • Johnson & Johnson Services, Inc.
  • Santen Inc.
  • Qlaris Bio, Inc.
  • Allergan Plc.
  • Cipla Inc.
  • Alcon Inc.

第22章策略建议

第23章关于我们公司，免责声明

Global glaucoma market is projected to witness a CAGR of 5.15% during the forecast period 2024-2031, growing from USD 8.53 billion in 2023 to USD 12.75 billion in 2031. The market demand for glaucoma treatment is anticipated to thrive drastically in the forecast years due to rising prevalence and the growing interest of investors and market players.

Glaucoma is a group of eye conditions that affect the optic nerve. This optic nerve transmits visual information from your eye to your brain and is quintessential for good vision. Glaucoma is usually associated with damage to the optic nerve, often due to high pressure inside the eye, though it can occur with normal eye pressure. Glaucoma can be present at any age but occurs more often with advancing age. It is one of the major causes of blindness in patients older than 60 years of age. The symptoms of glaucoma are based on the type and stage of your condition. The most common type of glaucoma is open-angle glaucoma and other types are less common, like angle-closure glaucoma. Open-angle glaucoma shows no symptoms in early stage, just patchy blind spot in side vision. Acute angle-closure glaucoma symptoms are severe headache, blurred vision, eye redness, severe eye pain, nausea and vomiting. At present, there are 80 million people worldwide affected with glaucoma. More than 3 million Americans are affected with glaucoma; of these, 2.7 million (aged 40 and older) have its most common type, open-angle glaucoma. As per the report published in June 2023, by Glaucoma Journal, it is estimated that by 2040, there will be 22 million blind people around the world affected with glaucoma. The World Glaucoma Week is an international initiative organized by the World Glaucoma Association. They invite patients, eye care providers, health officials, and the community to partner together in planning advocacy activities globally. Glaucoma is the leading cause of preventable blindness, and unique challenges exist in various parts of the world. The goal here is to enlighten everyone to check their eyes and optic nerves regularly so that glaucoma can be detected as early as possible and treatment can begin to prevent vision loss.

Rising Prevalence of Glaucoma Disease

The increasing prevalence of glaucoma also poses public health concerns for reasons other than the aging global population. It is a leading cause of irreversible blindness, and its prevalence is expected to soar in the future. Factors involved include aging demographics - for example, an increasing population older than 60 years and the risk of developing glaucoma increases with age. In addition, increased knowledge and changes in the methods of diagnosis have led to a higher detection of the disease, which underlines the prevalence of the disease. Socioeconomic factors such as urbanization also play a key role. They can aggravate risk factors like hypertension and diabetes associated with glaucoma. Consequently, the control of the rising prevalence of the disease constitutes a significant aspect of public health efforts and healthcare systems in the worldr. For instance, on 22 September 2022, Santen and UBE announced the Food and Drug Administration approval for Omlonti (omidenepag isopropyl ophthalmic solution) 0.002% eye drops for the reduction of intraocular pressure in adults with open-angle glaucoma or ocular hypertension. Omlonti, the active pharmaceutical ingredient is omidenepag isopropyl, which is a relatively selective prostaglandin EP2 receptor agonist that increases aqueous humor drainage through the conventional (or trabecular) and uveoscleral outflow pathways.

Increasing Awareness and Advancement in Technology Brings Glaucoma Market Growth

Advanced treatments for glaucoma have dramatically changed the treatment of the disease, offering patients much more effective and targeted alternative therapies. Some of the recent innovations in pharmacotherapy involve entirely new classes of drugs, such as Rho kinase inhibitors, which represent an alternative means of lowering intraocular pressure. In addition, sustained-release drug delivery systems and implantable devices offer a degree of increased consistency with regard to adherence to any prescribed medication regimen and decreased side effects. Less-invasive surgical techniques, especially microinvasive glaucoma surgery (MIGS), have proven effective in the management of glaucoma with less time to recover and reduced morbidity compared with conventional surgeries. Such developments not only improve patient outcomes but also bring up the quality of life in patients suffering from the disease, thus making it crucial to continue further research and development work in this most critical area of eye care. For instance, in May 2024, Lupin Global, a pharmaceutical giant got approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for travoprost ophthalmic solution USP, 0.004% (ionic buffered solution). Travoprost ophthalmic solution USP, 0.004%, is indicated for lowering of intraocular pressure in patients diagnosed with open-angle glaucoma or ocular hypertension.

Rising Prevalence of Open Angle Glaucoma Segment to Dominate the Glaucoma Market

Open-angle glaucoma is expected to be a key driver for growth in this market in the face of the increasing incidence of open-angle glaucoma. Open Angle Glaucoma is the most common type of glaucoma and usually lacks symptoms in the early stages, thereby developing an increasing population that is untreated and undiagnosed as awareness increases. This is highly significant within aging populations, since the incidence of eye diseases is more prevalent within such populations. Advancements in diagnostic technologies and treatments, such as topical medications and surgical interventions, will continue to fuel further growth in the market. A focus on early detection and management of Open Angle Glaucoma to prevent vision loss is further likely to invest research and development efforts as well as increase patient education - which will have a positive impact on the market dynamics anticipated to rise in the future due to improved diagnostics facilities which enable more patients to be treated promptly. For instance, on 14 December 2022, Thea Pharma, Inc., the U.S. subsidiary of Europe's leading independent pharmaceutical company, announced the U.S. Food and Drug Administration (FDA) approval for the New Drug Application (NDA) of IYUZEH (latanoprost ophthalmic solution) 0.005% for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

North America Dominates the Glaucoma Market

North America currently dominates the glaucoma market, driven by a combination of advanced healthcare infrastructure, high awareness of eye health. Glaucoma is one of the major causes of irreversible blindness in the United States. More than 3 million Americans suffer from glaucoma. It is expected that by 2050, this number will increase to 6.3 million because of the aging US population. Glaucoma costs the US economy USD 2.86 billion every year through direct costs and loss of productivity. This region has a highly integrated network of ophthalmologists and eye care specialists that helps patients have proper treatment options at the right time. In terms of government initiatives and collaboration by private sectors, advanced treatments will be accessible. Robust reimbursement policies also sustain good care for patients. North America is likely to continue at the top, with its contribution expected to play a huge role in ongoing developments and new approaches for the prevention and management of glaucoma. For instance, on 15 December 2023, the United States Food and Drug Administration approved a new treatment for glaucoma, iDose TR (travoprost intracameral implant, 75 mcg). The new iDose TR is the first and only device of its kind that is specifically developed to offer up to three years of 24/7, continuous drug therapy directly inside the eye, helping patients suffering with glaucoma take control of the elevated eye pressure associated with this vision disease.

Future Market Scenario (2024-2031F)

The future market scenario for the glaucoma market appears promising and is characterized by significant advancements in technology and treatment options. The future of glaucoma management will change dramatically with emerging novel therapies, such as neuroprotective agents and minimally invasive surgical techniques. Ideally, telemedicine and other digital health solutions are expected to come in, making it easier for patients to adhere and monitor themselves. Moreover, increasing awareness and education will continue to result in earlier diagnoses. As a result, the prevalence of vision loss is likely to decrease. In addition, the increasing global demographics and an ageing population around the world will also increase demand for effective glaucoma treatments, resulting in significant demand and investment in the sector. For instance, sustained-release glaucoma drug delivery systems are currently being developed or are in the pipeline. Latanoprost punctal plug delivery system L-PPDS (Evolute, Mati Therapeutics, Austin, TX, USA) is a punctal plug loaded with prostaglandin analogs, it is currently in Phase II clinical trial.

Key Players Landscape and Outlook

Glaucoma market is mainly dominated by market players like Allergen Plc., Merck & Co., Inc. and many more. Market activity reported in recent years includes business agreements, collaborations, and regulatory approvals of market players' products. The market fosters several smaller players as well, which operate through collaborations with other players to cater to a larger market.

For instance, in May 2024, Merck (MRK.N) agreed to buy privately held biotech EyeBio for as much as USD 3 billion, in a deal aimed at adding treatments for eye diseases to the company's portfolio of experimental drugs. The maker will pay USD 1.3 billion in cash and another USD 1.7 billion in milestone-based payments upon future milestones with EyeBio, along with an agreement for access to a retinal disease drug called Restoret.

For instance, in July 2024, Alcon inks USD 466M deal for Belkin Vision's automated laser therapy for treat glaucoma. The deal includes an upfront payment of USD 81 million that includes about USD 65 million in cash-plus the chance at up to USD 385 million more in sales-based milestone payments, Alcon be able to get the technology into the hands of clinicians as first-line therapy.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Glaucoma Market Outlook, 2017-2031F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Disease Type
    • 4.2.1.1. Open Angle Glaucoma
    • 4.2.1.2. Angle Closure Glaucoma
    • 4.2.1.3. Others
  • 4.2.2. By Drug Class
    • 4.2.2.1. Prostaglandins Analog
    • 4.2.2.2. Adrenergic Agonist
    • 4.2.2.3. Beta-Blockers
    • 4.2.2.4. Carbonic Anhydrase Inhibitors
    • 4.2.2.5. Others
  • 4.2.3. By Distribution
    • 4.2.3.1. Hospital Pharmacies
    • 4.2.3.2. Retail Pharmacies
    • 4.2.3.3. Online Pharmacies
    • 4.2.3.4. Others
  • 4.2.4. By Region
    • 4.2.4.1. North America
    • 4.2.4.2. Europe
    • 4.2.4.3. Asia-Pacific
    • 4.2.4.4. South America
    • 4.2.4.5. Middle East and Africa
  • 4.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
• 4.3. Market Map Analysis, 2023
  • 4.3.1. By Disease Type
  • 4.3.2. By Drug Class
  • 4.3.3. By Distribution
  • 4.3.4. By Region

5. North America Glaucoma Market Outlook, 2017-2031F*

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Disease Type
    • 5.2.1.1. Open Angle glaucoma
    • 5.2.1.2. Angle Closure Glaucoma
    • 5.2.1.3. Others
  • 5.2.2. By Drug Class
    • 5.2.2.1. Prostaglandins Analog
    • 5.2.2.2. Adrenergic Agonist
    • 5.2.2.3. Beta-Blockers
    • 5.2.2.4. Carbonic Anhydrase Inhibitors
    • 5.2.2.5. Others
  • 5.2.3. By Distribution
    • 5.2.3.1. Hospital Pharmacies
    • 5.2.3.2. Retail Pharmacies
    • 5.2.3.3. Online Pharmacies
    • 5.2.3.4. Others
  • 5.2.4. By Country Share
    • 5.2.4.1. United States
    • 5.2.4.2. Canada
    • 5.2.4.3. Mexico
• 5.3. Country Market Assessment
  • 5.3.1. United States Glaucoma Market Outlook, 2017-2031F*
    • 5.3.1.1. Market Size Analysis & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share Analysis & Forecast
      • 5.3.1.2.1. By Disease Type
        • 5.3.1.2.1.1. Open Angle Glaucoma
        • 5.3.1.2.1.2. Angle Closure Glaucoma
        • 5.3.1.2.1.3. Others
      • 5.3.1.2.2. By Drug Class
        • 5.3.1.2.2.1. Prostaglandins Analog
        • 5.3.1.2.2.2. Adrenergic Agonist
        • 5.3.1.2.2.3. Beta-Blockers
        • 5.3.1.2.2.4. Carbonic Anhydrase Inhibitors
        • 5.3.1.2.2.5. Others
      • 5.3.1.2.3. By Distribution
        • 5.3.1.2.3.1. Hospitals Pharmacies
        • 5.3.1.2.3.2. Retail Pharmacies
        • 5.3.1.2.3.3. Online Pharmacies
        • 5.3.1.2.3.4. Others
  • 5.3.2. Canada
  • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Glaucoma Market Outlook, 2017-2031F

• 6.1. Germany
• 6.2. France
• 6.3. Italy
• 6.4. United Kingdom
• 6.5. Russia
• 6.6. Netherlands
• 6.7. Spain
• 6.8. Poland

7. Asia-Pacific Glaucoma Market Outlook, 2017-2031F

• 7.1. India
• 7.2. China
• 7.3. Japan
• 7.4. Australia
• 7.5. Vietnam
• 7.6. South Korea
• 7.7. Indonesia
• 7.8. Philippines

8. South America Glaucoma Market Outlook, 2017-2031F

• 8.1. Brazil
• 8.2. Argentina

9. Middle East and Africa Glaucoma Market Outlook, 2017-2031F

• 9.1. Saudi Arabia
• 9.2. UAE
• 9.3. South Africa
• 9.4. Israel

10. Demand Supply Analysis

11. Import and Export Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

• 16.1. Market Drivers
• 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework and Innovation

• 18.1. Clinical Trials
• 18.2. Regulatory Approvals

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

• 21.1. Competition Matrix of Top 5 Market Leaders
• 21.2. SWOT Analysis for Top 5 Players
• 21.3. Key Players Landscape for Top 10 Market Players
  • 21.3.1. Merck & Co., Inc.
    • 21.3.1.1. Company Details
    • 21.3.1.2. Key Management Personnel
    • 21.3.1.3. Products and Services
    • 21.3.1.4. Financials (As Reported)
    • 21.3.1.5. Key Market Focus and Geographical Presence
    • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 21.3.2. Pfizer Inc.
  • 21.3.3. Novartis AG.
  • 21.3.4. Teva Pharmaceuticals Industries Ltd.
  • 21.3.5. Johnson & Johnson Services, Inc.
  • 21.3.6. Santen Inc.
  • 21.3.7. Qlaris Bio, Inc.
  • 21.3.8. Allergan Plc.
  • 21.3.9. Cipla Inc.
  • 21.3.10. Alcon Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Glaucoma Market, By Value, In USD Billion, 2017-2031F
• Figure 2. Global Glaucoma Market Share (%), By Disease Type, 2017-2031F
• Figure 3. Global Glaucoma Market Share (%), By Drug Class, 2017-2031F
• Figure 4. Global Glaucoma Market Share (%), By Distribution, 2017-2031F
• Figure 5. Global Glaucoma Market Share (%), By Region, 2017-2031F
• Figure 6. North America Glaucoma Market, By Value, In USD Billion, 2017-2031F
• Figure 7. North America Glaucoma Market Share (%), By Disease Type, 2017-2031F
• Figure 8. North America Glaucoma Market Share (%), By Drug Class, 2017-2031F
• Figure 9. North America Glaucoma Market Share (%), By Distribution, 2017-2031F
• Figure 10. North America Glaucoma Market Share (%), By Country, 2017-2031F
• Figure 11. United States Glaucoma Market, By Value, In USD Billion, 2017-2031F
• Figure 12. United States Glaucoma Market Share (%), By Disease Type, 2017-2031F
• Figure 13. United States Glaucoma Market Share (%), By Drug Class, 2017-2031F
• Figure 14. United States Glaucoma Market Share (%), By Distribution, 2017-2031F
• Figure 15. Canada Glaucoma Market, By Value, In USD Billion, 2017-2031F
• Figure 16. Canada Glaucoma Market Share (%), By Disease Type, 2017-2031F
• Figure 17. Canada Glaucoma Market Share (%), By Drug Class, 2017-2031F
• Figure 18. Canada Glaucoma Market Share (%), By Distribution, 2017-2031F
• Figure 19. Mexico Glaucoma Market, By Value, In USD Billion, 2017-2031F
• Figure 20. Mexico Glaucoma Market Share (%), By Disease Type, 2017-2031F
• Figure 21. Mexico Glaucoma Market Share (%), By Drug Class, 2017-2031F
• Figure 22. Mexico Glaucoma Market Share (%), By Distribution, 2017-2031F
• Figure 23. Europe Glaucoma Market, By Value, In USD Billion, 2017-2031F
• Figure 24. Europe Glaucoma Market Share (%), By Disease Type, 2017-2031F
• Figure 25. Europe Glaucoma Market Share (%), By Drug Class, 2017-2031F
• Figure 26. Europe Glaucoma Market Share (%), By Distribution, 2017-2031F
• Figure 27. Europe Glaucoma Market Share (%), By Country, 2017-2031F
• Figure 28. Germany Glaucoma Market, By Value, In USD Billion, 2017-2031F
• Figure 29. Germany Glaucoma Market Share (%), By Disease Type, 2017-2031F
• Figure 30. Germany Glaucoma Market Share (%), By Drug Class, 2017-2031F
• Figure 31. Germany Glaucoma Market Share (%), By Distribution, 2017-2031F
• Figure 32. France Glaucoma Market, By Value, In USD Billion, 2017-2031F
• Figure 33. France Glaucoma Market Share (%), By Disease Type, 2017-2031F
• Figure 34. France Glaucoma Market Share (%), By Drug Class, 2017-2031F
• Figure 35. France Glaucoma Market Share (%), By Distribution, 2017-2031F
• Figure 36. Italy Glaucoma Market, By Value, In USD Billion, 2017-2031F
• Figure 37. Italy Glaucoma Market Share (%), By Disease Type, 2017-2031F
• Figure 38. Italy Glaucoma Market Share (%), By Drug Class, 2017-2031F
• Figure 39. Italy Glaucoma Market Share (%), By Distribution, 2017-2031F
• Figure 40. United Kingdom Glaucoma Market, By Value, In USD Billion, 2017-2031F
• Figure 41. United Kingdom Glaucoma Market Share (%), By Disease Type, 2017-2031F
• Figure 42. United Kingdom Glaucoma Market Share (%), By Drug Class, 2017-2031F
• Figure 43. United Kingdom Glaucoma Market Share (%), By Distribution, 2017-2031F
• Figure 44. Russia Glaucoma Market, By Value, In USD Billion, 2017-2031F
• Figure 45. Russia Glaucoma Market Share (%), By Disease Type, 2017-2031F
• Figure 46. Russia Glaucoma Market Share (%), By Drug Class, 2017-2031F
• Figure 47. Russia Glaucoma Market Share (%), By Distribution, 2017-2031F
• Figure 48. Netherlands Glaucoma Market, By Value, In USD Billion, 2017-2031F
• Figure 49. Netherlands Glaucoma Market Share (%), By Disease Type, 2017-2031F
• Figure 50. Netherlands Glaucoma Market Share (%), By Drug Class, 2017-2031F
• Figure 51. Netherlands Glaucoma Market Share (%), By Distribution, 2017-2031F
• Figure 52. Spain Glaucoma Market, By Value, In USD Billion, 2017-2031F
• Figure 53. Spain Glaucoma Market Share (%), By Disease Type, 2017-2031F
• Figure 54. Spain Glaucoma Market Share (%), By Drug Class, 2017-2031F
• Figure 55. Spain Glaucoma Market Share (%), By Distribution, 2017-2031F
• Figure 56. Turkey Glaucoma Market, By Value, In USD Billion, 2017-2031F
• Figure 57. Turkey Glaucoma Market Share (%), By Disease Type, 2017-2031F
• Figure 58. Turkey Glaucoma Market Share (%), By Drug Class, 2017-2031F
• Figure 59. Turkey Glaucoma Market Share (%), By Distribution, 2017-2031F
• Figure 60. Poland Glaucoma Market, By Value, In USD Billion, 2017-2031F
• Figure 61. Poland Glaucoma Market Share (%), By Disease Type, 2017-2031F
• Figure 62. Poland Glaucoma Market Share (%), By Drug Class, 2017-2031F
• Figure 63. Poland Glaucoma Market Share (%), By Distribution, 2017-2031F
• Figure 64. South America Glaucoma Market, By Value, In USD Billion, 2017-2031F
• Figure 65. South America Glaucoma Market Share (%), By Disease Type, 2017-2031F
• Figure 66. South America Glaucoma Market Share (%), By Drug Class, 2017-2031F
• Figure 67. South America Glaucoma Market Share (%), By Distribution, 2017-2031F
• Figure 68. South America Glaucoma Market Share (%), By Country, 2017-2031F
• Figure 69. Brazil Glaucoma Market, By Value, In USD Billion, 2017-2031F
• Figure 70. Brazil Glaucoma Market Share (%), By Disease Type, 2017-2031F
• Figure 71. Brazil Glaucoma Market Share (%), By Drug Class, 2017-2031F
• Figure 72. Brazil Glaucoma Market Share (%), By Distribution, 2017-2031F
• Figure 73. Argentina Glaucoma Market, By Value, In USD Billion, 2017-2031F
• Figure 74. Argentina Glaucoma Market Share (%), By Disease Type, 2017-2031F
• Figure 75. Argentina Glaucoma Market Share (%), By Drug Class, 2017-2031F
• Figure 76. Argentina Glaucoma Market Share (%), By Distribution, 2017-2031F
• Figure 77. Asia-Pacific Glaucoma Market, By Value, In USD Billion, 2017-2031F
• Figure 78. Asia-Pacific Glaucoma Market Share (%), By Disease Type, 2017-2031F
• Figure 79. Asia-Pacific Glaucoma Market Share (%), By Drug Class, 2017-2031F
• Figure 80. Asia-Pacific Glaucoma Market Share (%), By Distribution, 2017-2031F
• Figure 81. Asia-Pacific Glaucoma Market Share (%), By Country, 2017-2031F
• Figure 82. India Glaucoma Market, By Value, In USD Billion, 2017-2031F
• Figure 83. India Glaucoma Market Share (%), By Disease Type, 2017-2031F
• Figure 84. India Glaucoma Market Share (%), By Drug Class, 2017-2031F
• Figure 85. India Glaucoma Market Share (%), By Distribution, 2017-2031F
• Figure 86. China Glaucoma Market, By Value, In USD Billion, 2017-2031F
• Figure 87. China Glaucoma Market Share (%), By Disease Type, 2017-2031F
• Figure 88. China Glaucoma Market Share (%), By Drug Class, 2017-2031F
• Figure 89. China Glaucoma Market Share (%), By Distribution, 2017-2031F
• Figure 90. Japan Glaucoma Market, By Value, In USD Billion, 2017-2031F
• Figure 91. Japan Glaucoma Market Share (%), By Disease Type, 2017-2031F
• Figure 92. Japan Glaucoma Market Share (%), By Drug Class, 2017-2031F
• Figure 93. Japan Glaucoma Market Share (%), By Distribution, 2017-2031F
• Figure 94. Australia Glaucoma Market, By Value, In USD Billion, 2017-2031F
• Figure 95. Australia Glaucoma Market Share (%), By Disease Type, 2017-2031F
• Figure 96. Australia Glaucoma Market Share (%), By Drug Class, 2017-2031F
• Figure 97. Australia Glaucoma Market Share (%), By Distribution, 2017-2031F
• Figure 98. Vietnam Glaucoma Market, By Value, In USD Billion, 2017-2031F
• Figure 99. Vietnam Glaucoma Market Share (%), By Disease Type, 2017-2031F
• Figure 100. Vietnam Glaucoma Market Share (%), By Drug Class, 2017-2031F
• Figure 101. Vietnam Glaucoma Market Share (%), By Distribution, 2017-2031F
• Figure 102. South Korea Glaucoma Market, By Value, In USD Billion, 2017-2031F
• Figure 103. South Korea Glaucoma Market Share (%), By Disease Type, 2017-2031F
• Figure 104. South Korea Glaucoma Market Share (%), By Drug Class, 2017-2031F
• Figure 105. South Korea Glaucoma Market Share (%), By Distribution, 2017-2031F
• Figure 106. Indonesia Glaucoma Market, By Value, In USD Billion, 2017-2031F
• Figure 107. Indonesia Glaucoma Market Share (%), By Disease Type, 2017-2031F
• Figure 108. Indonesia Glaucoma Market Share (%), By Drug Class, 2017-2031F
• Figure 109. Indonesia Glaucoma Market Share (%), By Distribution, 2017-2031F
• Figure 110. Philippines Glaucoma Market, By Value, In USD Billion, 2017-2031F
• Figure 111. Philippines Glaucoma Market Share (%), By Disease Type, 2017-2031F
• Figure 112. Philippines Glaucoma Market Share (%), By Drug Class, 2017-2031F
• Figure 113. Philippines Glaucoma Market Share (%), By Distribution, 2017-2031F
• Figure 114. Middle East & Africa Glaucoma Market, By Value, In USD Billion, 2017-2031F
• Figure 115. Middle East & Africa Glaucoma Market Share (%), By Disease Type, 2017-2031F
• Figure 116. Middle East & Africa Glaucoma Market Share (%), By Drug Class, 2017-2031F
• Figure 117. Middle East & Africa Glaucoma Market Share (%), By Distribution, 2017-2031F
• Figure 118. Middle East & Africa Glaucoma Market Share (%), By Country, 2017-2031F
• Figure 119. Saudi Arabia Glaucoma Market, By Value, In USD Billion, 2017-2031F
• Figure 120. Saudi Arabia Glaucoma Market Share (%), By Disease Type, 2017-2031F
• Figure 121. Saudi Arabia Glaucoma Market Share (%), By Drug Class, 2017-2031F
• Figure 122. Saudi Arabia Glaucoma Market Share (%), By Distribution, 2017-2031F
• Figure 123. UAE Glaucoma Market, By Value, In USD Billion, 2017-2031F
• Figure 124. UAE Glaucoma Market Share (%), By Disease Type, 2017-2031F
• Figure 125. UAE Glaucoma Market Share (%), By Drug Class, 2017-2031F
• Figure 126. UAE Glaucoma Market Share (%), By Distribution, 2017-2031F
• Figure 127. South Africa Glaucoma Market, By Value, In USD Billion, 2017-2031F
• Figure 128. South Africa Glaucoma Market Share (%), By Disease Type, 2017-2031F
• Figure 129. South Africa Glaucoma Market Share (%), By Drug Class, 2017-2031F
• Figure 130. South Africa Glaucoma Market Share (%), By Distribution, 2017-2031F
• Figure 131. By Disease Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 132. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 133. By Distribution Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023